

Ensayos Clínicos de **TIROIDES** Abiertos a Reclutamiento (actualizado junio 2020)

| EudraCT_Number | NCT | CODIGO_ESTUDIO | TITULO DEL ESTUDIO | FASE_ESTUDIO | INDICACION | ESTADO | MEDICACION | CENTROS_PARTICIPANTES | PROMOTOR | ESPECIALIDAD | COMENTOS |
|--------------------------------|-------------------------|----------------------|---|---------------------------|--|--------------------|--|--|--|---------------------------------|----------|
| 2018-003612-27 | 3780517 | BOS172738-01 | A Phase 1 Study of ROS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC) | Phase I | Advanced Nonhaematologic Malignancies | RECLUTANDO | BOS172738 | H.U.V Victoria (Málaga) ; ICO-Badalona (BCN) H.U. Quiron Dexeus(BCN) CIOCC - START (Madrid); H.U.I.D. START (Madrid) | Boston Pharmaceuticals | Oncologia_Medica | N= 114 |
| 2016-004390-41 | 3037385 | BLU-667-1101 (ARROW) | A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors | Phase I/II | RET-altered NSCLC Medullary Thyroid Cancer RET-altered Colon Cancer RET-altered Solid Tumors | RECLUTANDO | BLU-667 | H.U.Vall d'Hebron (BCN) H.U.Clinic(BCN) ICO-Hospitalet (BCN) H.U.Ramon y Cajal (Madrid) H.U.12 Octubre (Madrid) | Blueprint Medicines Corporation | Oncologia_Medica | N= 360 |
| 2017-000800-59 | 3157128 | LOXO-RET-17001 | A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) | Phase I / II | This is a Phase 1/2, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selipratinib (also known as LOXO-292) administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation. | RECLUTANDO | LOXO-292 | H.U.Vall d'Hebron (BCN) H.U.Clinic(BCN) ICOS Hospital (BCN) F.J. Diaz (Madrid) START_Sanchinarro (Madrid) | Loxo Oncology, Inc | Oncologia_Medica | N= 970 |
| 2017-001792-24 | 3170960 | XL184-021 | A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Phase Ib | Expansion Cohort 1b: DTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI. | RECLUTANDO | Drug: atezolizumab Drug: cabozantinib | H.U.Vall d'Hebron(BCN) C.M.Telmo (BCN) H.Clinic (BCN) H.Mar (BCN) C.H.U.Santiago H.U.Son Espases(I.B) H.U.12 Octubre (Madrid) | Exelixis | Oncologia_medica | N= 1732 |
| 2016-002422-62 | 2988817 | GCT1021-01 | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Anti-specific Antibody-conjugate (Enapatamab Vedotin, HuMax [®] -AXL-ADC) in Patients With Solid Tumors | Phase I/II | The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors. Thyroid Cancer | Not yet Recruiting | Biological: Enapatamab vedotin (HuMax-AXL-ADC) | H.C.Lozano Blas(Zaragoza) H.U.Ramon y Cajal (Madrid) H.U.Puerta Hierro (Madrid) H.U.12 Octubre (Madrid) ICO-Girona Hospitalet(BCN) H.U.Vall d'Hebron (BCN) | ICO- Genmab | Oncologia_medica | N= 374 |
| 2015-002067-41 | 2628067 | 3475-158 | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) | Phase II | Thyroid Carcinoma Salivary Gland Carcinoma (Sarcomas and mesenchymal tumors are excluded) | RECLUTANDO | Pembrolizumab | H.U.Vall d'Hebron(BCN) H.U.Ramon y Cajal (Madrid) H.U.12 Octubre (Madrid) | Merck Sharp & Dohme Corp | Oncologia_Medica | N= 1350 |
| 2015-001385-84 | 2568267 | RKDX-101-02 | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | Phase II | Head and Neck Neoplasms, Papillary Thyroid Cancer, Salivary Gland Cancers, Adult Solid Tumor | RECLUTANDO | Entrectinib | H.U.Vall d'Hebron (BCN) H.U.Ramon y Cajal (Madrid) H.U.Clinico San Carlos(Madrid) H.U.12 Octubre (Madrid) START -CIOCC (Madrid) H.U.V.Victoria (Málaga) H.U.V.Rocio (Sevilla) | Hoffmann-La Roche / Ignyta, Inc | Oncologia_Medica | N= 300 |
| 2018-001066-42 | 3753919 | GETNE-T1812 | Estudio de fase II de durvalumab (MED4736) más tremelimumab para el tratamiento de pacientes con carcinoma tiroideo avanzado, resistente al tratamiento y progresivo (ensayo DUTHY) | Phase II | Carcinoma de tiroides diferenciado, avanzado, refractario al yodo radiactivo, incluyendo carcinoma tiroideo papilar, foliolar, de células de Hürthle y poco diferenciado (CMT) Carcinoma medular de tiroides (CMT) avanzado. Cáncer anaplásico de tiroides (CAT) avanzado. | RECLUTANDO | Durvalumab (I.V) | C.U. Navarra H.Vall d'Hebron ICO, Hospitalet BCN H.U.Morales Meseguer (Murcia) H.U.Ramon y Cajal (Madrid) H.U.12 Octubre (Madrid) H.U.La Paz (Madrid) H.U.Victoria (Málaga) H.U.Clinic (BCN) M.D.Anderson(Madrid) H.U.San Chinarro (Madrid) H.C.U.San Carlos(Madrid) C.H.Castellon I.VG.Valencia H.U.Abevero Cuencuetro (Vigo) | Spanish Group of Neuroendocrine Tumors (GETNE) | Oncologia Medica | N= 46 |
| 2018-001771-21 | 3690388 | XL184-311 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy | Phase III | The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior VEGFR-Targeted therapy. | RECLUTANDO | Cabozantinib | H.U.12 Octubre(Madrid) H.C.U.San Carlos (Madrid) H.U.Ramon y Cajal (Madrid) H.U.La Paz (Madrid) H.U.San Chinarro (Madrid) M.D.Anderson (Madrid) C.U.Navarra H.U.Vall d'Hebron (Madrid) H.U.V.Victoria (Málaga) H.Clinic (BCN) | Exelixis | Oncologia_medica | N= 300 |
| 2019-001978-28 | 4211337 | I2G-MC-JZIB | A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selipratinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) | Phase III | The reason for this study is to see if the study drug selipratinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. | RECLUTANDO | Drug: Selipratinib Drug: Cabozantinib Drug: Vandetanib | H.V.Victoria(Málaga) H.Clinico (Madrid) H.U.12 Octubre (Madrid) H.U.La Paz (Madrid) H.U.Ramon y Cajal (Madrid) H.U.G.Marañon(Madrid) ICO_Girona ICO, Hospitalet H.U.Vall d'Hebron (BCN) C.U.Navarra (Pamplona) C.U.Navarra(Madrid) H.U.Miguel Servet (Zaragoza) | Lilly | Oncologia_medica | N= 400 |
| 2013-003402-40 | 1896479 | XL184-401 | Estudio aleatorizado y doble ciego para evaluar la eficacia y la seguridad de cabozantinib (XL184) con dosis de 60 mg/día en comparación con 140 mg/día en pacientes con cáncer medular de tiroides metastásico progresivo | Phase IV | CMT metastásico progresivo | RECLUTANDO | Cabozantinib (Oral) | H.La Paz, H.Vall d'Hebron, H.Ramon y Cajal. | Exelixis, Inc | Oncología (La Paz: Endocrinio) | N=188 |
| UK | 3765333 | REGETNE-Tiroides | Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic | Descriptive Observational | NA | RECLUTANDO | NA | H.U.Vall d'Hebron | GETNE | Oncologia_Medica | N= 20 |
| UK | 1945762 | D4200C0004 | European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer | Observational Prospective | Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer (MTC) | RECLUTANDO | Vandetanib 300mg | 1 Site Barcelona H.U.12 Octubre | Genzyme, a Sanofi Company | Oncologia_Medica | N= 80 |